News | April 20, 2026
Rusan Pharma secures Japan PMDA GMP approval for API, FDF facilities
PMDA is regarded among the most stringent regulatory bodies globally
PMDA is regarded among the most stringent regulatory bodies globally
The inspection is now closed, and no regulatory action has been recommended
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The audit was completed with zero critical and zero major observations
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
